Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-Phenylpiperazine is a simple chemical compound consisting of a phenyl group bound to a piperazine ring. It serves as the parent structure for a wide range of bioactive derivatives known as substituted phenylpiperazines. Pharmacologically, it acts primarily as a monoamine releasing agent with modest selectivity for norepinephrine over serotonin and dopamine. Its EC50 values indicate it is about five times more potent at releasing norepinephrine than serotonin and over thirteen times more potent than dopamine release. The compound itself has limited direct therapeutic use but is widely utilized in pharmaceutical research and drug development as an intermediate or reference standard. It also plays roles in neurotransmitter research (notably involving serotonin and dopamine receptors), behavioral studies in animal models related to psychoactive substances and addiction mechanisms, analytical chemistry (as a standard), and material science applications[2][6][7]. At high doses it can be toxic; its oral LD50 in rats is reported at 210 mg/kg[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-phenylpiperazine.